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Venlafaxine treatment reduces
the deficit of executive control of
attention in patients with major
depressive disorder
Yanghua Tian1,*, Jing Du2,*, Alfredo Spagna3,*, Melissa-Ann Mackie3,*, Xiaosi Gu4, Yi Dong5,
Jin Fan3,6,7 & Kai Wang1
Attention plays an essential role in supporting other cognitive functions and behavior, and disturbance
of attention is one of the most common symptoms in major depressive disorder (MDD). Although
treatment with venlafaxine for MDD symptoms has been shown to reduce deficits in cognition and
emotion regulation, it remains unclear whether venlafaxine improves specific attentional functions.
We used the Attention Network Test to measure the attentional functions of alerting, orienting,
and executive control before and after treatment with venlafaxine in patients with MDD compared
to untreated healthy controls. Before treatment, the MDD group showed a selective impairment in
alerting and executive control of attention, while there were no significant group differences in the
orienting function. The interaction between group and session was significant for executive control, and
after treatment with venlafaxine, the performance of the MDD group on executive control of attention
was not significantly different from that of controls. Reported symptoms of MDD were also significantly
reduced after treatment with venlafaxine. These results demonstrate that treatment with venlafaxine
selectively normalizes the executive control function of attention in addition to improving clinical
symptoms in MDD.
Major depressive disorder (MDD) is the most common type of psychiatric disorder, with lifetime prevalence
estimates of more than 3.5% in China1. In addition to mood symptoms, it is often associated with deficits in attention2–4, executive functions4–6, and processing speed5,7. These are considered to be primary features of the disorder
and have a negative impact on functional and social ability8–10. Attention plays an essential role in supporting
other cognitive functions and behavior, and its disturbance is one of the most common symptoms in MDD, with
frequent complaints of difficulty maintaining concentration10. A wealth of studies have provided empirical evidence for these attention deficits, such as in the alerting2,3,11 and orienting11 functions of attention, although some
controversy still exists4,11. However, whether current pharmacological interventions are effective in the treatment
of these deficits is unclear. Hence, a comprehensive assessment of treatment outcomes should investigate the
change in cognitive functions, such as attention, together with changes in the clinical symptoms.
Attention can be conceptualized as three separable functions of alerting, orienting, and executive control,
supported by corresponding brain networks and neurotransmitter systems12,13. Alerting contributes to the maintenance of readiness and has been associated with activation in the thalamus, and frontal and parietal cortical
regions14, and with the cortical distribution of the norepinephrine (NE) neurotransmitter system15. Orienting
is responsible for selecting and moving attention to stimuli, and is supported by frontal and parietal regions
and the acetylcholine (Ach) neurotransmitter system16,17. Executive control is involved in resolving conflicts
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Sex (Female/Male)

MDD (n =  34)

HC (n =  30)

Test

p

24/10

19/11

χ2 =  0.38

0.54

Age in years

36.1 ±  13.3

34.2 ±  12.2

t =  0.58

0.56

Education in years

10.6 ±  3.9

10.8 ±  3.8

t =  0.29

0.78

MMSE

29.3 ±  1.2

29.5 ±  0.8

t =  0.68

0.45

Table 1. Demographic data of patients with MDD and healthy controls (Mean ± SD). Note: MMSE =  Minimental state examination.
and coordinating among thoughts and actions18,19, and often activates areas in the frontoparietal network (FPN)
including the anterior cingulate cortex (ACC) and other frontoparietal regions14,20, and is modulated by the
mesocortical dopamine (DA) system21. The efficiency of these attentional functions can be measured using the
Attention Network Test (ANT)13. Using this paradigm, selective and multiple attentional function impairments
have been found to be associated with different psychiatric disorders22,23. Although previous studies have examined specific attentional function deficits in MDD using other tasks2–4,24, the selective impairment of attention in
MDD and treatment effects on attention are still unclear.
Deficits in attentional systems may be linked to dysfunction in specific neurotransmitter systems that have
been associated with MDD. Specifically, dysfunctions in serotonin (5-HT), NE, and DA systems have been consistently associated with MDD25 and current antidepressant treatments act on these neurotransmitters to reduce
the clinical symptoms. Venlafaxine is an antidepressant in a group of drugs called serotonin-norepinephrine
reuptake inhibitors (SNRI), and is recognized as a safe, rapidly effective, and widely used antidepressant26,27.
Its main mechanism of action is the inhibition of 5-HT reuptake, with dose-dependent inhibition of NE reuptake28, and weak DA reuptake inhibition29. Furthermore, there is evidence that venlafaxine might also increase
dopamine levels in striatum, hippocampus, and frontal brain regions28,30–32. Given that venlafaxine acts on neurotransmitters systems relevant to attention, and the persistence of attentional deficits in patients with MDD33, it
is important to clarify whether treatment with this antidepressant also treats deficits in the attentional functions.
The present study examined the effects of treatment with venlafaxine on the attentional deficits associated
with MDD. Because NE and DA are implicated in the neurobiology of MDD, we hypothesized that patients with
MDD would show impairment in the alerting and executive control functions. Importantly, because venlafaxine
acts upon these neurotransmitters, we also hypothesized that the treatment with venlafaxine would reduce these
attentional deficits.

Results

Clinical symptoms and treatment effects. There were no significant differences between the MDD and
HC groups in age, education, or MMSE scores (see Table 1). In the MDD group, the 24-item Hamilton Rating
Scale for Depression (HRSD)34 scores decreased significantly from the pre-test (37.5 ± 5.8) to post-test session
(4.5 ±  5.6), (t(33) =  25.4, p < 0.001). The Self-Rating Depression Scale (SDS)35 scores also decreased significantly
from pre-test (51.8 ± 9.4) to post-test (29.3 ±  5.6), (t(33) =  12.1, p < 0.001). See Fig. 1 for the treatment effects of
clinical symptoms.
Overall reaction time and error rate.

Table 2 and Fig. 2 show the overall reaction time (RT) and error
rate (ER) group differences. Trials with 3 standard deviations (SD) above the mean RT were considered outliers
and excluded from further analysis. For the overall RT, the main effect of Group was significant (F(1,62) =  15.4,
p < 0.001) indicating that the MDD group (683 ± 120 ms) responded significantly slower than the HC group
(584 ± 84 ms). The main effect of Session was significant (F(1,62) =  32, p < 0.001) indicating that RT was reduced
from pre-test (661 ± 136 ms) to post-test (611 ± 95 ms). The Group by Session interaction was significant
(F(1,62) =  10.7, p < 0.05). Simple comparisons revealed that in the MDD group, RT decreased significantly from
pre-test (721 ± 141 ms) to post-test session (644 ± 100 ms) (F(1,62) =  42.7, p < 0.01), while the difference in RT
between the two sessions (594 ± 91 ms and 573 ± 73 ms, respectively) in the HC group was not significant
(F(1,62) =  2.7, p =  0.10).
For the overall ER, the main effect of Group was significant (F(1,62) =  4.1, p < 0.05), indicating that the HC
group (3.1 ± 2.9%) made more errors than the MDD group (1.9 ± 2.3%). The main effect of Session was not significant (F(1,62) =  3.5, p = 0.07). The Group by Session interaction was significant (F(1,62) =  6.4, p <  0.05). Simple
comparisons revealed that the ER was significantly reduced from the pre-test session (2.6 ± 3.1%) to the post-test
session (1.2 ±  1.3%) (F(1,62) =  10.3, p < 0.01) in the MDD group, while the difference in the ER between the two
sessions (3.0 ± 2.8% and 3.2 ± 3.1%, respectively) in the HC group was not significant (F <  1).

Attentional deficits and treatment effects.

groups within the two sessions.

Table 2 and Fig. 3 show the attentional effects for both

The alerting effect. For RT, the main effect of Group was significant (F(1,62) =  12.3, p < 0.05), indicating a smaller
alerting effect in the MDD group (27 ± 30 ms) compared to the HC group (39 ± 23 ms). The main effect of Session
was not significant (F(1,62) =  1.7, p = 0.19 ). The Group by Session interaction was not significant (F(1,62) =  1.8,
p = 0.19). For ER, the main effects of Group (F(1,62) =  1.4, p = 0.24), and Session (F < 1), and the Group by Session
interaction (F < 1) were not significant.
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Figure 1. Clinical symptom scores at pre- and post-test in MDD patients treated with venlafaxine. Note:
**p <  0.01.

The orienting effect. For RT, the main effects of Group and Session (Fs < 1) and the Group by Session interaction effect (F(1,62) =  1.1, p = 0.29) were not significant. For ER, the main effects of Group (F < 1) and Session
(F(1,62) =  2.0, p = 0.15 ), and the Group by Session interaction (F < 1) were not significant.
The executive control effect. For the RT, the main effect of Group was not significant (F(1,62) =  3.1, p =  0.09).
The main effect of Session was significant (F(1,62) =  13.2, p < 0.01), indicating a greater conflict effect in the
pre-test (98 ± 38 ms) compared to post-test (post 85 ± 37 ms). The Group by Session interaction was significant (F(1,62) =  4.9, p < 0.05). Simple comparisons indicated that the executive control effect was significantly
reduced from pre-test session (109 ± 43 ms) to post-test session (88 ± 41 ms) in the MDD group (F(1,62) =  18.3,
p < 0.01), while the difference in the conflict effect between the two sessions was not significant for the HC group
(F < 1). The post-test difference in the conflict effect between the HC and the MDD groups was not significant (F(1,62) = .84; p = .36). Bayesian t test for accepting or rejecting the null hypothesis (http://pcl.missouri.edu/
bf-two-sample) favored the null. For ER, the main effects of Group (F < 1), Session (F < 1), and the Group by
Session interaction (F < 1) were not significant.
Correlations between attentional functions and clinical scores. There were no significant correlations between
attentional functions and symptom scores of the HRSD and SDS neither at pre-test, nor between the attentional
effect change and symptom change scores at post-test.

Discussion

This study demonstrated slower overall response speed in the MDD group, as well as pre-treatment attentional
deficits in the alerting and executive control functions of attention. This result is consistent with other studies
showing that depression is associated with deficits in executive control4–6,36. The executive control of attention has
been extensively related to the activity of several frontal and parietal areas (FPN37), and in particular to the activation of the ACC, which depends on the mesocortical DA system38–40. Hypofunction and abnormal structure in
ACC have been shown to be associated with major depression41,42. Therefore, the impairment of executive control
function in MDD may be caused by dysfunction of this region within the FPN.
Furthermore, venlafaxine treatment selectively improved the executive control component of attention. This
observed selective treatment effect may be due to direct and indirect effects of this medication on the DA system
which improved the efficiency of this function within the patient group. Previous studies have demonstrated
that venlafaxine increases DA level in frontal lobe and limbic system30–32. Furthermore, there is abundant physiological evidence for complex modulation and interactions between 5-HT and DA systems within the frontal
lobes. 5-HT has been shown to have an inhibitory effect on DA neurotransmission43,44, and a reduction in available 5-HT, as implicated in the neurobiology of MDD, may result in release from inhibition of the DA system,
Scientific Reports | 6:28028 | DOI: 10.1038/srep28028
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Figure 2. Overall reaction time and error rate for MDD and HC groups in the pre- and post-test sessions.
Patients with MDD showed a significantly slower responding speed than controls in pre-test session. After
treatment with venlafaxine, there was a significant improvement in response time in the MDD group. Note: **
p <  0.01.

MDD (n =  34)

HC (n =  30)

Pre-test

Post-test

Pre-test

Post-test
573 (75)

Reaction Time
Overall

721 (141)

644 (100)

594 (91)

Alerting

25 (28)

29 (32)

36 (23)

42 (23)

Orienting

54 (38)

54 (23)

59 (21)

51 (21)

Executive control

109 (43)

88 (41)

86 (31)

81 (32)

Error Rate
Overall

2.6 (3.3)

1.2 (1.3)

3.0 (2.8)

3.2 (3.1)

Alerting

0.2 (3.5)

0.2 (2.4)

−0.5 (3.5)

−0.6 (2.8)

Orienting

0.9 (3.7)

0.1 (1.6)

0.7 (3.2)

−0.02 (2.5)

Executive control

2.8 (5.6)

1.8 (2.2)

1.7 (2.9)

1.6 (2.2)

Table 2. Attention network scores for Reaction Time (SD), in ms, and Error Rate (SD), in percent, of MDD
and HC groups.
resulting in impulsivity, a hallmark of deficient executive control. Consequently, increasing the availability of
5-HT within frontal cortex via SNRI treatment may account for improvement of the executive control of attention45,46. However, further investigations that directly compare drugs designed to target different neurotransmitter systems are needed in order to draw strong conclusions about the specificity of these mechanisms.
The improvement of executive control of attention is not trivial. A previous study demonstrated that this attentional function contributes significantly to the implementation of cognitive control, which is necessary for executing high-level cognitive functions47. The efficiency of cognitive control and executive functions is directly related
to functional outcomes in MDD48,49. Furthermore, cognitive control is involved in emotion regulation50 and the
suppression of dysfunctional thoughts51, which are common in MDD. Consequently, treatment of this attention
component may result in improvement in cognitive control, emotion regulation, and in overall daily functioning.
Based on the deficient NE neurotransmission associated with MDD, we also predicted that the patient group
would show a deficit of the alerting function (which is related to the NE system52), and that this deficit would be
reduced by venlafaxine. The reduced alerting effect observed in the patient group suggests a lower level of readiness to respond to external stimuli2. However, we did not find evidence of a treatment effect with venlafaxine
on the alerting deficit. It has been noted that the inhibition of reuptake of NE typically occurs at dosage greater
than 150 mg/day28,53; 150 mg/day was the maximum dose used in this study and therefore may not have been high
enough to directly act on the NE system. Given that typical maximum clinical doses can be as high as 375 mg per
day, and previous evidence indicating that significant effects on the noradrenergic system are achieved only with
high doses of venlafaxine54, it is possible that higher dosages than were used in this study might have a treatment
effect on the alerting function, though higher doses tend to increase the likelihood of adverse side effects55.
The prediction that there would be no deficit in the orienting of attention associated with MDD, as shown in
previous studies2,4, was confirmed also by our results. Furthermore, venlafaxine does not act on the cholinergic
system28, and we did not expect any change in the orienting function due to the treatment. Previous studies have
demonstrated that both the depletion of 5-HT and NE-blocking drugs, the two mechanisms by which venlafaxine
exerts its effect, have no influence on the orienting performance56,57.
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Figure 3. The attentional effects for the MDD group and for to the HC group in the pre- and post-test
sessions. In the pre-test session, the MDD group showed a selective impairment in alerting and executive
control of attention in reaction time. In the post-test session, the performance of the MDD group on executive
control of attention was not significantly different from that of HC in reaction time. Note: *p <  0.05.
Although cognitive impairments are nowadays often associated with major depression5, the relationship
between attentional deficits and clinical symptoms of MDD is still under debate. For example, there is some
evidence showing that the cognitive deficits and clinical symptoms may be due to abnormalities of cortical and
subcortical regions, however, the cognitive impairment seems to be more durable than the clinical symptoms58.
In the current study, although the treatment with venlafaxine reduced the deficit in the executive control function together with effectively reducing the clinical symptomatology, the changes in the two measures were not
correlated, which may suggest that the attentional deficits and symptom severity may arise from independent
mechanisms.
There are some limitations to this study that may restrict the strength of the conclusions. The sample size in
this study was relatively limited, and a larger study would allow for stronger conclusions about the attentional
deficits and treatment effects. Furthermore, because all patients received treatment with venlafaxine only, we were
not able to compare the effects of different types of antidepressants on attentional functions. Such a comparison
could help to further clarify the role of intervening at the level of neurotransmission to improve the cognitive and
clinical symptoms of MDD. Future studies may also aim to increase the treatment duration (longer than the six
weeks in this study) to determine the optimal treatment length for maximum gain in attentional improvement.
In conclusion, we found that there were deficits in the alerting and executive control of attention in MDD, and
showed that venlafaxine selectively improved the executive control of attention. There was no evidence for deficits
in the orienting function. Antidepressants that improve cognitive function in addition to clinical symptoms have
great potential to reduce the functional impairment associated with MDD.

Methods

Participants. Fifty-three patients with MDD were recruited from Anhui Mental Health Center affiliated with
Anhui Medical University, China. Diagnosis of MDD was by consensus of two independent psychiatrists using
the Structured Clinical and Interview for DSM-IV. MDD participants were drug naïve or drug free for at least
3 months prior to the study, and only patients eligible for venlafaxine treatment were recruited and were monitored for dose titration and adverse side effects. The 24-item HRSD and SDS were used to measure the severity of
Scientific Reports | 6:28028 | DOI: 10.1038/srep28028
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Figure 4. Experimental procedure: (a) the four cue conditions; (b) the three target conditions (six target types)
used in the present experiment; and (c) an example of the procedure. In this task, participants made responses
to indicate the direction of a central arrow (left or right).

clinical symptoms. The Mini-Mental State Examination (MMSE)59 was administered to all participants and only
those who scored higher than 27 were included in order to exclude mild cognitive impairment and dementia.
Patients with a history of brain tumor, stroke, or other neurological disease that could interrupt brain function
were excluded. Four patients showing intolerance to the treatment with venlafaxine were excluded from this study
and received an alternative antidepressant treatment. In total, 19 patients discontinued their participation in this
study. The final MDD sample consisted of thirty-four patients (10 males and 24 females; mean age =  36 ±  13
years; average years of education =  11 ±  4 years).
Thirty healthy controls (HC; 11 males and 19 female) were recruited (mean age =  34 ± 12.2 years; average
years of education =  11 ± 4 years). HC participants were evaluated by staff psychiatrists, and individuals with
history of neurological, psychiatric, or systemic medical disorders were not included. All participants had normal or corrected to normal vision and gave written informed consent. The ethical committee of Anhui Medical
University approved this study, and methods and procedures of this study were in accordance with the approved
guidelines.

Attention Network Test. Figure 4 illustrates the stimuli and sequence of events in the ANT. Stimuli consisted of a row of five visually presented horizontal black lines, with arrowheads pointing leftward or rightward,
against a gray background. The target was a left- or right-pointing arrowhead in the center, flanked on either side
by two arrows pointing in the same direction (congruent condition), or in the opposite direction (incongruent
condition), or by horizontal lines (neutral condition). A single arrow or line extended 0.55° of the visual angle
and the contours of adjacent arrows or lines were separated by 0.06° of the visual angle. The row of five stimuli
was presented at 1.06° either above or below the central fixation cross. Participants were asked to identify the
direction of the central arrow by pressing one computer mouse button for the left direction and a second button
for the right direction. Cues consisted of a 100 ms asterisk presented 400 ms before the target. There were four
cue conditions: (1) no-cue, in which the central fixation cross remained present and unchanged; (2) central-cue,
which appeared at the central fixation point; (3) double-cue, in which cues were presented on the two possible target locations simultaneously; and (4) spatial-cue, in which the cue was presented at the location of the upcoming
target. The task consisted of a 24-trial practice block and three experimental blocks of trials. Each experimental
block consisted of 96 trials (48 conditions: 4 warning levels × 2 target locations × 2 target directions ×  3 congruency conditions, with 2 repetitions). The presentation of trials was randomized. Participants were instructed to
fixate at a centrally located cross throughout the task, and to respond as quickly and accurately as possible.
Effects for each attentional function were calculated based on the RT and ER data. The alerting effect was
calculated by subtracting the mean RT of the double cue condition from the mean RT of the no cue condition.
The orienting effect was calculated by subtracting the mean RT of the spatial cue condition from the mean RT
of the center cue condition. For the ER computations of alerting and orienting, the subtractions were reversed
to yield positive effect scores. The executive control effect was calculated by subtracting the mean RT (or ER) of
congruent conditions from the mean RT (or ER) of incongruent conditions. The calculations of attentional effects
are described in detail in a previous publication13.
Procedure. In the pre-test session, participants from both groups completed the MMSE, and the ANT. The
MDD group also completed the HRSD and SDS. MDD patients were then treated with venlafaxine with a starting
dose of 75 mg, gradually increased up to 75–150 mg daily. At the 6-week time point (post-test session) the MDD
group then completed the ANT, HRSD and SDS again. During the six-week period, patients did not receive any
other treatment. The untreated HC group was also post-tested on the ANT after a 6-week interval.
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Data Analysis.

Mixed factorial analyses of variance with Group (HC, MDD) as the between-subjects factor
and Session (pre-test, post-test) as the within-subjects factor were performed on each attentional effect in both
RT and ER. Simple comparisons were used to further analyze significant interaction effects. Spearman correlation analyses were conducted between attentional effects and pre-test clinical symptoms, and between changes
(pre-test minus post-test) in the attentional effects and changes in the clinical symptoms after venlafaxine treatment, and a corrected critical αvalue of p < 0.01 was used.
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